Inspection Record

Pendopharm, Division of Pharmascience Inc — Health Canada Inspection Findings

Health CanadaInspected 2023-03-07 5 findingsDeviation, CAPA, and investigationOther quality systemComplaint and recall handling

View the regulator's official source The source document is always the basis for judgement.

Findings

1Deviation, CAPA, and investigation

Investigations into deviations, reports, and/or follow-up actions were inadequate.

2Other quality system

The implementation of a self-inspection program was inadequate.

3Other quality system

Documents were not available on the premises.

5Other quality system

Complete testing was not performed according to the requirements.

About this record

Extracted automatically from the document of the Health Canada inspection on 2023-03-07. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Pendopharm, Division of Pharmascience Inc company profile — full historyAll Health Canada findings Health Canada documents, 2023 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.